Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
German state railway loss widens, passengers warned of trouble ahead - 2Desired Travel Objections Worldwide: Where to Go Straightaway
- 3Blake Lively's sexual harassment claims against Justin Baldoni dismissed. Where the case stands now.
- 4Building a Flourishing Business: Illustrations from Business people
- 5Good ways to respond if your kid brings home less-than-ideal grades
- Hundreds are quarantined in South Carolina as measles spreads in 2 US outbreaks
- Pat Finn, actor from 'The Middle,' dies at 60 after bladder cancer diagnosis
- Step by step instructions to Pick the Right Dental specialist for Your Teeth Substitution
- Artemis II astronauts channel Apollo 8 with a striking Earthset photo
- From Educational Loans to Obligation Free: Independence from the rat race Accomplished
- 6 US States for Fly Fishing
- FDA claims on COVID-19 vaccine safety are unsupported by reliable data – and could severely hinder vaccine access
- Iranian naval commander Alireza Tangsiri killed in attack, says Israel
- The World's Dazzling Regular Miracles
